Formulary Group work programme


Forthcoming submissions 2014

This list is indicative and may be subject to change.

Aflibercept - SMC 1003/14 Formulary Group advice will be published by 30th December 2014. (Indication: for adults for the treatment of visual impairment due to diabetic macular oedema (DMO)).

Atomoxetine - SMC 909/13 - in progress. (Indication: treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme).

Cholecalciferol oral solution - SMC 1011/14 - Formulary Group advice will be published 30th December 2014. (Indication: the prevention and treatment of vitamin D deficiency).

Clindamycin/tretinoin gel (Treclin®) - SMC 1010/14 - Formulary Group advice will be published by 30th December 2014. (Indication: for the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older).

Dolutegravir, abacavir, lamivudine (Triumeq®) - SMC 1009/14 - Formulary Group advice will be published by 30th December 2014. (Indication: for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg).

Eltrombopag - SMC 919/13 - in progress. (Indication: in adult patients with chronic hepatitis C virus infection, for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy).

Everolimus - SMC 595/10Formulary Group advice will be published by 30th December 2014. (Indication: the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy).

Ganciclovir eye gel - FG1 375/14 - in progress. (Indication: local treatment of herpes simplex infection (ocular)).

Harvoni® - FG1 378/14 - Formulary group advice will be published by 30th December 2014. (Indication: Chronic hepatitis C).

Indacaterol maleate plus glycopyrronium bromide (Ultibro® Breezhaler®) - SMC 922/13 - Formulary Group advice will be published by 30th December 2014. (Indication: maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)).

Nalmefene - SMC 917/13 - in progress. (Indication: for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms, and who do not require immediate detoxification).

Nepafenac - SMC 813/12 - in progress. (Indication: reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients).

Obinutuzumab - SMC 1008/14 - Formulary Group advice will be published by 30th December 2014. (Indication: in combination with chlorambucil, obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy).

Ocriplasmin - SMC 892/13 - in progress. (Indication: in adults for the treatment of vitreomacular traction).

Ondanestron - SMC 912/13 - in progress. (Indication: in adults: prophylaxis and treatment of acute and delayed nausea and vomiting induced by chemotherapy, and radiotherapy. Prophylaxis and treatment of post-operative nausea and vomiting.
In paediatric populations: management of chemotherapy-induced nausea and vomiting in children aged ≥6 months and prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged ≥4 years).

Pemetrexed - SMC 770/12 - Formulary Group advice will be published by 30th December 2014. (Indication: monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy).

Pomalidomide - SMC 972/14 - Formulary Group advice will be published by 30th December 2014. (Indication: in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma).

Riociguat - SMC 1001/14 - Formulary Group advice will be published by 30th December 2014. (Indication: Chronic thromboembolic pulmonary hypertension (CTEPH)).

Rituximab subcutaneous injection - SMC 975/14 - in progress. (Indication: for non-Hodgkin's lymphoma (NHL) in adults).

Triamcinolone - FG1 363/14 - in progress. (Indication: Cystoid Macular Oedema (CMO)).

Umeclidinium - SMC 1004/14 - Formulary Group advice will be published by 30th December 2014. (Indication: as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END

« Previous: Formulary Group | Top | Next: Formulary Group decisions index »